Clinical trial · Interventional
Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
A Randomized, Open Label Phase II Study of OSI-211 vs Topotecan in Patients With Advanced and/or Recurrent Epithelial Ovarian Cancer
NCT00046800CI-TRIAL-00005660completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Neoplasms | Ovarian Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| OSI-211 (Liposomal Lurtotecan) | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed relapsed ovarian cancer. * Measurable disease greater than or equal to 20 mm (or greater than or equal to 10 mm on spiral CT scan). * One or two prior regimens of chemotherapy. At least one regimen must have contained cisplatin or carboplatin. * At least three weeks since prior chemotherapy and recovery from any related toxicities. * At least four weeks since prior radiotherapy and recovery from any related toxicities.
References
Publications (0)
Data not yet available
No reference posted for this study.